Dr. Reddy's Laboratories Ltd. (RDY)

34.70
0.17 0.49
NYSE : Health Technology
Prev Close 34.87
Open 34.67
Day Low/High 34.58 / 34.87
52 Wk Low/High 28.13 / 42.97
Volume 220.79K
Avg Volume 474.50K
Exchange NYSE
Shares Outstanding 165.87M
Market Cap 5.80B
EPS 0.90
P/E Ratio 38.48
Div & Yield 0.28 (0.84%)

Latest News

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2018 was filed with the United States...

Dr. Reddy's Laboratories Limited To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Dr. Reddy's Laboratories Limited To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13 th, 2018, in California.

Dr. Reddy's Laboratories Limited To Present At The Jefferies 2018 Healthcare Conference

Dr. Reddy's Laboratories Limited To Present At The Jefferies 2018 Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Jefferies 2018 Healthcare Conference on Wednesday, June 6 th, 2018, in New York City.

Dr. Reddy's To Release Q4 And Full Year FY18 Results On May 22, 2018

Dr. Reddy's To Release Q4 And Full Year FY18 Results On May 22, 2018

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Fourth Quarter and Full year ended March 31, 2018 on Tuesday, May 22, 2018 after the Board Meeting.

Dr. Reddy's Laboratories And Its U.S. Subsidiary Promius Pharma Announce The Filing Of An NDA For Its Migraine Candidate

Dr. Reddy's Laboratories And Its U.S. Subsidiary Promius Pharma Announce The Filing Of An NDA For Its Migraine Candidate

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application (NDA) for its migraine candidate DFN-02 with the U.

Dr. Reddy's Laboratories Announces Senior Leadership Changes

Dr. Reddy's Laboratories Announces Senior Leadership Changes

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Announces The Launch Of Levocetirizine Dihydrochloride Tablets USP, 5 Mg In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Levocetirizine Dihydrochloride Tablets USP, 5 Mg In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of...

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

A massive price-fixing lawsuit brought by 45 states against a group of generic drug producers as well as a changing of the guard at the Food and Drug Administration may lead to changes in the generic drug sector.

Dr. Reddy's Laboratories Announces The Launch Of Tetrabenazine Tablets In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Tetrabenazine Tablets In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine® (tetrabenazine) in the United States...

Dr. Reddy's Laboratories is Now Oversold (RDY)

Dr. Reddy's Laboratories is Now Oversold (RDY)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

RDY Crosses Below Key Moving Average Level

RDY Crosses Below Key Moving Average Level

In trading on Thursday, shares of Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Q3 And 9M FY18 Financial Results

Dr. Reddy's Q3 And 9M FY18 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q3 FY18 Results On January 25, 2018

Dr. Reddy's To Release Q3 FY18 Results On January 25, 2018

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Third Quarter ended December 31, 2017 on Thursday, January 25, 2018 after the Board Meeting.

Dr. Reddy's Laboratories Limited To Present At The 36th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Laboratories Limited To Present At The 36th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124)(NSE: DRREDDY)(NYSE: RDY) announced that the Company will be presenting at the 36th Annual J.

Dr. Reddy's Laboratories Announces The Launch Of Melphalan Hydrochloride For Injection In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Melphalan Hydrochloride For Injection In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran® (melphalan...

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.

Dr. Reddy's Q2 And H1 FY18 Financial Results

Dr. Reddy's Q2 And H1 FY18 Financial Results

Dr. Reddy's Laboratories Ltd.

DR. REDDY'S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)

DR. REDDY'S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against Dr.

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of October 24th Lead Plaintiff Deadline In Securities Class Action Against Dr. Reddy's Laboratories Limited (RDY)

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of October 24th Lead Plaintiff Deadline In Securities Class Action Against Dr. Reddy's Laboratories Limited (RDY)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that October 24 th is the deadline for lead plaintiff motions in the securities class...

DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Dr.

Dr. Reddy's To Release Q2 FY18 Results On October 31, 2017

Dr. Reddy's To Release Q2 FY18 Results On October 31, 2017

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2017 on Tuesday, October 31, 2017 after the Board Meeting.

TheStreet Quant Rating: C (Hold)